SCHEMBL15908347

SCHEMBL15908347

C=CCOC1(CC=C)c2ccccc2CCc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 6/20 0.40
ADRA2A P08913 2/20 0.35
ADRA2B P18089 2/20 0.35
ADRA2C P18825 2/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HTR2A P28223 1/20 0.33
LMNA P02545 1/20 0.32
PRCP P42785 2/20 0.32
CYP3A4 P08684 2/20 0.31
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8506381 0.73 SIGMAR1 (0.38) SIGMAR1ADRA2AMEN1KMT2AALDH1A1
SCHEMBL10952661 0.73 LMNA (0.49) SIGMAR1MAPK1SMN1; SMN2HTR2ALMNA
SCHEMBL8507270 0.72 PGR (0.38) SIGMAR1ADRA2AMEN1KMT2AALDH1A1
SCHEMBL29501701 0.69 SIGMAR1 (0.43) SIGMAR1ALDH1A1TDP1HTR2ACYP3A4
SCHEMBL8507250 0.69 CCR1 (0.42) SIGMAR1MEN1ALDH1A1HTR2ALMNA
SCHEMBL7936583 0.69 CHRM2 (0.40) SIGMAR1ADRA2ATDP1HTR2ALMNA
SCHEMBL9240715 0.68 KDM1A (0.40) SIGMAR1MEN1KMT2AALDH1A1TDP1
SCHEMBL9281778 0.67 SIGMAR1 (0.51) SIGMAR1MEN1KMT2AMAPK1HTR2A
SCHEMBL4736099 0.67 KDM1A (0.42) SIGMAR1MEN1KMT2AALDH1A1TDP1
SCHEMBL4734271 0.67 KDM1A (0.42) SIGMAR1MEN1KMT2AALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540358-B2 Tricyclic compounds as anticancer agents ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-01-10 US disclosed
US-9540358-B2 Tricyclic compounds as anticancer agents ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-01-10 US disclosed
US-20140213578-A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS MT. SINAI SCHOOL OF MEDICINE (US) 2014-07-31 US disclosed
US-20140213578-A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS MT. SINAI SCHOOL OF MEDICINE (US) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213578-A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS TFEB, FOXO3, FOXO1 SIGMAR1 3567/4885ADRA2A 2643/4885ADRA2B 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.